Clinical outcomes and predictive factors in oral corticosteroid-refractory active ulcerative colitis

Table 2 Comparison of clinical factors in immediate outcomes of the two groups of active ulcerative colitis patients receiving intravenous corticosteroids after oral corticosteroid therapy failure

	Responders (n = 56)	Non-responders1 (n = 11)	P-value		Odds ratio (95%CI)
			Univariate	Multivariate
Gender (M/F)	32/24 (57.1/42.9)	7/4 (63.6/36.4)	0.690
Age (yr)	37 (13-78)	39 (29-50)	0.458
Disease duration (mo)
≤ 24	34 (60.7)	3 (27.3)	0.041	0.123	3.38 (0.72-15.88)
> 24	22 (39.3)	8 (72.7)
First attack of UC	26 (46.4)	6 (54.5)	0.273
Disease extent			0.884
Proctitis	4 (7.1)	1 (9.1)
Left-sided colitis	17 (30.4)	4 (36.4)
Extensive colitis	35 (62.5)	6 (54.5)
Disease activity
Full Mayo score (< 9/≥ 9)	27/24 (52.9/47.1)	3/8 (27.3/72.7)	0.122
Partial Mayo score (< 6/≥ 6)	14/42 (25/75)	1/10 (9.1/90.9)	0.227
Initial prednisolone dose (mg)			0.622
≥ 30 and < 40	29 (51.8)	6 (54.5)
≥ 40	27 (48.2)	5 (45.5)
Duration of oral corticosteroid use (d)
≤ 14	33 (58.9)	3 (27.3)	0.054	0.049	4.9 (1.01-23.81)
> 14	23 (41.1)	8 (72.7)
Concomitant medications			0.809
Salicylates	44 (78.6)	9 (81.8)
Azathioprine	12 (21.4)	2 (18.2)
CRP (mg/dL)
≤ 8	37 (66.1)	11 (84.6)	0.303
> 8	19 (33.9)	2 (15.4)
ESR (mm/h)	40 (3-120)	40 (12-83)	0.999
Hemoglobin (mg/dL)
≤ 11	18 (32.1)	8 (72.7)	0.012	0.02	0.16 (0.03-0.75)
> 11	38 (67.9)	3 (27.3)
Albumin (mg/dL)	3.63 (2.3-5.0)	3.56 (2.8-4.8)	0.331

¹Non-responder group included patients that had secondary alternative drug use, proctocolectomy and death before day 14. M/F: Male/female; UC: Ulcerative colitis; CRP: C-reactive protein; ESR: Erythrocyte sedimentation rate.